From Des Moines, Iowa, USA:
My three year old niece was diagnosed with typeá1 diabetes after she was hospitalized for 40 days with E-coli [bacterial] complications. After my sister insisted on a second opinion, it was determined through an antibody test that she is not type 1. Even though her C-peptide levels are low, her hemoglobin A1c is good. Can she be put on pills? She has been having trouble with being low. In fact if she gets below 90 mg/dl [5 mmol/L], she complains of hunger, back aches and is grumpy. What should their next step or tests be?
With an acute onset of insulin dependent diabetes, but with a negative antibody test and a low C-peptide test, the diagnosis would now be called typeá1B diabetes. This is quite rare in Caucasian children, but common in Hispanic and African American new onset cases. The underlying pathology is not yet well understood though some are linked to chromosomal changes. Unlike typeá2 diabetes in children they are basically insulin deficient, not insulin resistant. Many of them though can be taken off insulin after some weeks and managed on oral hypoglycemic agents and even occasionally with diet and exercise. In the long term, it seems probable that most will require insulin supplementation. I don't think any further tests are needed, but her mother should talk all this over with the doctor and perhaps just try an oral hypoglycemic like Glucophage [metformin] to see if the present excellent control is maintained with less risk of hypoglycemia.
Original posting 2 Apr 2001
Posted to Daily Care
Last Updated: Tuesday April 06, 2010 15:09:20
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents.
© Children with Diabetes, Inc. 1995-2016. Comments and Feedback.